Ipsen Expands In Oncology With New Pacts

French Firm Ups BD Activity

After CEO David Loew declared again that Ipsen would be very active in the dealmaking space, Ipsen is paying $45m upfront to access two immuno-oncology candidates from Marengo and bagged an ERK inhibitor from AGV Discovery.

Ipsen
• Source: Alamy

Ipsen SA's appetite for business development has not been sated and just over a month after agreeing to acquire Epizyme, Inc., the French firm has furthered its cancer pipeline by getting access to compounds from Marengo Therapeutics and AGV Discovery.

First up, Ipsen has agreed to pay $45m upfront to help advance two immuno-oncology candidates generated by Marengo’s Selective T...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip